Healthcare issues for children on the autism spectrum

Current Opinion in Psychiatry

Volumn 19, Issue 4, 2006, Pages 361-366

  Volkmar, Fred R ^a,b   Wiesner, Lisa A ^a   Westphal, Alexander ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Autism; Healthcare; Measles mumps rubella vaccine; Screening

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; MEASLES MUMPS RUBELLA VACCINE; SECRETIN; SEROTONIN UPTAKE INHIBITOR;

ANXIETY DISORDER; AUTISM; BEHAVIOR THEORY; CHILD; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EPILEPSY; FRAGILE X SYNDROME; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HUMAN; IMMUNIZATION; INTERNATIONAL CLASSIFICATION OF DISEASES; MOOD DISORDER; OCCUPATIONAL THERAPY; PHYSIOTHERAPY; PSYCHOSIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SCREENING; SEIZURE; TUBEROUS SCLEROSIS;

AUSTRALIA; AUTISTIC DISORDER; CHILD; CHILD HEALTH SERVICES; CHILD, PRESCHOOL; CROSS-CULTURAL COMPARISON; HUMANS; INCIDENCE; QUESTIONNAIRES; UNITED STATES;

EID: 33748254300     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000228754.64743.66     Document Type: Review

References (56)

1. Volkmar FR, Klin A. Issues in the classification of autism and related conditions. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 5-41.
2. Acker RV, Loncola JA, Acker EYV. Rett syndrome: a pervasive developmental disorde. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 126-164.
3. Klin A, Pauls D, Schultz R, Volkmar F. Three diagnostic approaches to Asperger syndrome: implications for research. J Autism Dev Disord 2005; 35:221-234.
4. Rutter M. Genetic influences and autism. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 425-452. A truly masterful summary of what is known about the genetics of autism and related conditions.
5. Glasson EJ, Bower C, Petterson B, et al. Perinatal factors and the development of autism: a population study. Arch Gen Psychiatry 2004; 61:618-627.
6. Hultman CM, Sparen P. Autism - prenatal insults or an epiphenomenon of a strongly genetic disorder? Lancet 2004; 364:485-487.
7. Batshaw ML. Children with disabilities. 5th ed. Baltimore, MD: Brookes Publishing; 2002.
8. Volkmar F, Wiesner E. Health care for children on the autism spectrum. Bethesda, MD: Woodbine Publishing; 2004.
9. Hare DJ, Pratt C, Burton M, et al. The health and social care needs of family carers supporting adults with autistic spectrum disorders. Autism 2004; 8:425-444.
10. Krauss MW, Gulley S, Sciegaj M, Wells N. Access to specialty medical care for children with mental retardation, autism, and other special health care needs. Ment Retard 2003; 41:329-339.
11. Kanner L. Autistic disturbances of affective contact. Nervous Child 1943; 2:217-250.
12. Chawarska K, Volkmar F. Autism in infancy and early childhood. In: Volkmar F, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. New York: Wiley; 2005. pp. 223-246.
13. Siegel B, Pliner C, Eschler J, Elliott GR. How children with autism are diagnosed: difficulties in identification of children with multiple developmental delays. J Dev Behav Pediatr 1988; 9:199-204.
14. Heidgerken AD, Geffken G, Modi A, Frakey L. A survey of autism knowledge in a health care setting. J Autism Dev Disord 2005; 35:323-330.
15. Coonrod EE, Stone WL. Screening for autism in young children. In: Volkmar F, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. New York: Wiley; 2005. pp. 707-729. An excellent review of currently available screening instruments. Of particular interest to clinicians concerned with early diagnosis.
16. Klin A, Chawarska K, Paul R, et al. Autism in a 15-month-old child. Am J Psychiatry 2004; 161:1981-1988.
17. Lord C. Follow-up of two-year-olds referred for possible autism. J Child Psychol Psychiatry 1995; 36:1365-1382.
18. Klin A, Jones W, Schultz RT, Volkmar FR. The enactive mind from actions to cognition: lessons from autism. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 682-703.
19. Rogers SJ, DiLalla DL. Age of symptom onset in young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1990; 29:863-872.
20. Wakefield AJ, Murch SH, Anthony A, et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children [comment]. Lancet 1998; 351:637-641.
21. Taylor B, Miller E, Farrington CP, et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association [comment]. Lancet 1999; 353:2026-2029.
22. Smeeth L, Hall AJ, Fombonne E, et al. A case-control study of autism and mumps-measles-rubella vaccination using the general practice research database: design and methodology. BMC Public Health 2001; 1:2.
23. Chen W, Landau S, Sham P, Fombonne E. No evidence for links between autism, MMR and measles virus. Psychol Med 2004; 34:543-553.
24. Honda H, Shimizu Y, Rutter M. No effect of MMR withdrawal on the incidence of autism: a total population study. J Child Psychol Psychiatry 2005; 46:572-579. One of a series of studies failing to show a link between MMR and autism.
25. Fombonne E. Epidemiological studies of pervasive developmental disorders. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 42-69. A scholarly and comprehensive review of the epidemiology of autism; this chapter includes a discussion of possible changes in epidemiology over time and co-occurring medical and psychiatric conditions.
26. Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Association between thimerosal-containing vaccine and autism. JAMA 2003; 290:1763-1766.
27. Stehr-Green P, Tull P, Stellfeld M, et al. Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 2003; 25:101-106.
28. Rutter M, Bailey A, Bolton P, Le Couteur A. Autism and known medical conditions: myth and substance. J Child Psychol Psychiatry 1994; 35:311-322.
29. Gillberg C, Coleman M. Autism and medical disorders: a review of the literature. Dev Med Child Neurol 1996; 38:191-202.
30. Volkmar FR, Nelson DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry 1990; 29:127-129.
31. Minshew NJ, Sweeney JA, Bauman ML, Webb SJ. Neurologic aspects of autism. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 453-472.
32. Courchesne E, Pierce K. Brain overgrowth in autism during a critical time in development: implications for frontal pyramidal neuron and interneuron development and connectivity. Int J Dev Neurosci 2005; 23:153-170.
33. Howlin P. Outcomes in autism spectrum disorders. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 201-222.
34. National Research Council. Educating young children with autism. Washington, DC: National Academy Press; 2001.
35. Green J, Gilchrist A, Burton D, Cox A. Social and psychiatric functioning in adolescents with Asperger syndrome compared with conduct disorder. J Autism Dev Disord 2000; 30:279-293.
36. Klin A, McPartland J, Volkmar FR. Asperger syndrome. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 88-125.
37. Volkmar F, Cook EH Jr, Pomeroy J, et al. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. J Am Acad Child Adolesc Psychiatry 1999; 38 (12 Suppl):32S-54S.
38. Filipek PA, Accardo PJ, Ashwal S, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. Neurology 2000; 55:468-479.
39. Volkmar FR, Lord C, Bailey A, et al. Autism and pervasive developmental disorders. J Child Psychol Psychiatry 2004; 45:135-170.
40. Smith T, Groen AD, Wynn JW. Randomized trial of intensive early intervention for children with pervasive developmental disorder [erratum]. Am J Ment Retard 2001; 106:208.
41. Smith T, Antolovich M. Parental perceptions of supplemental interventions received by young children with autism in intensive behaviour analytic treatment. Behav Interv 2000; 15:83-97.
42. McDougle CJ, Scahill L, Aman MG, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2005; 162:1142-1148. One of a series of studies by the Research Units on Pediatric Psychopharmacology (RUPP) network. This report underscores the importance of controlled studies in assessing drug treatment in autism.
43. Hollander E, Phillips A, Chaplin W, et al. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviours in childhood and adolescent autism. Neuropsychopharmacology 2005; 30:582-589.
44. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioural problems [comment]. N Engl J Med 2002; 347:314-321.
45. Scahill L, Martin A. Psychopharmacology. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders, 3rd ed. Hoboken, NJ: Wiley; 2005. pp. 1102-1122. Outstanding summary of the state of the science of psychopharmacology and autism.
46. Jacobson JW, Foxx RM, Mulick JA, editors. Controversial therapies for developmental disabilities: fad, fashion and science in professional practice. Mahwah, NJ: Lawrence Erlbaum Associates Publishers; 2005. Although not limited to autism, this volume provides a truly comprehensive review of current alternative treatments.
47. Committee on Children with Developmental Disabilities. American Academy of Pediatrics: counseling families who choose complementary and alternative medicine for their child with chronic illness or disability. Committee on Children with Disabilities. Pediatrics 2001; 107:598-601.
48. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev 2005; 11:131-142.
49. Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2004; (2):CD003498.
50. Richardson AJ. Clinical trials of fatty acid treatment in ADHD, dyslexia, dyspraxia and the autistic spectrum. Prostaglandins Leukot Essent Fatty Acids 2004; 70:383-390.
51. Arnold GL, Hyman SL, Mooney RA, Kirby RS. Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord 2003; 33:449-454.
52. Horvath K, Stefanatos G, Sokolski KN, et al. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys 1998; 9:9-15.
53. Guerrini R, Parmeggiani L. Practitioner review: use of antiepileptic drugs in children. J Child Psychol Psychiatry 2006; 47:115-121.
54. Volkmar FR, Klin A, Siegel B, et al. Field trial for autistic disorder in DSM-IV. Am J Psychiatry 1994; 151:1361-1367.
55. Rogers SJ, Ozonoff S. What do we know about sensory dysfunction in autism? A critical review of the empirical evidence. J Child Psychol Psychiatry 2005; 46:1255-1268.
56. Baranek GT, Parham Li, Bodfish JW. Sensory and motor features in autism: assessment and intervention. In: Volkmar FR, Klin A, Paul R, Cohen DJ, editors. Handbook of autism and pervasive developmental disorders. 3rd ed. Hoboken, NJ: Wiley; 2005. 88-125.